A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Ceritinib (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Oct 2017 Planned primary completion date changed from 11 Sep 2017 to 11 Dec 2017.
    • 21 Jun 2017 Planned primary completion date changed from 11 Jun 2017 to 11 Sep 2017.
    • 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top